Search
CareDx Inc
CDNAAdd to Watchlist
19.970USD
-0.520-2.54%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
1.02BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-2.54%
5 Days
-8.48%
1 Month
-10.93%
6 Months
+25.32%
Year to Date
+6.00%
1 Year
+13.85%
TradingKey Stock Score of CareDx Inc
Currency: USD Updated: 2026-05-15Key Insights
CareDx Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 382 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 25.80.In the medium term, the stock price is expected to remain stable.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
CareDx Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
CareDx Inc Highlights
StrengthsRisks
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 35.49% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -126.01, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 52.46M shares, decreasing 15.72% quarter-over-quarter.
Held by First Eagle Investment
Star Investor First Eagle Investment holds 575.37K shares of this stock.
Analyst Rating
Based on
7
analysts
Buy
Current Rating
25.800
Target Price
+25.92%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
CareDx Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
CareDx Inc Info
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. It also offers a diverse portfolio of digital solutions to transplant centers.
Ticker SymbolCDNA
CompanyCareDx Inc
CEOHanna (John W)
Websitehttps://www.caredx.com/
Related Instruments
-0.03%
-1.77%
-1.75%
-0.15%
-1.11%
-1.79%
-2.22%
-1.88%
-2.35%
-1.63%
+0.43%
-2.99%
-0.37%
-1.64%
+1.79%
0.00%
-2.05%
-0.15%
-2.77%
+0.41%Popular Instruments
102.160
+3.297 (+3.33%)
300.230
+2.020 (+0.68%)
225.320
-10.420 (-4.42%)
4538.710
-111.520 (-2.40%)
482.020
-7.101 (-1.45%)
1407.610
+24.890 (+1.80%)
724.660
-51.350 (-6.62%)
396.780
-4.290 (-1.07%)
78231.000
-862.120 (-1.09%)
422.240
-21.060 (-4.75%)
